Clinical trials: Oncology Patients
Lung Neoplasms, Psychological Distress
Association of Psychological Distress in Patients With Lung Cancer
Psychological distress is a multi-factorial experience of a psychological, social, spiritual, and/or physical nature that may interfere with one's ability to cope effectively with cancer, physical symptoms and treatment.
- Conditions
- Lung Neoplasms, Psychological Distress, Prognosis Factors, Lifestyle, Healthy
- Trial name
- Life-Score (NCT06218901)
- Testing
- immunotherapy, Targeted Therapy Agent
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Shanghai Chest Hospital
Glioblastoma Multiforme
Radiosurgery for Glioblastoma Multiforme
Conventional radiation for 6 weeks is not well tolerated by the elderly. Shorter courses (over 3-5 weeks) of radiation have been shown to be equivalent in outcome the elderly- particularly in patients who are generally in poor…
- Trial name
- NCT00456612
- Testing
- CyberKnife
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Beth Israel Deaconess Medical Center
NSCLC Adenocarcinoma, Solid Tumor
Atamparib in Patients With Advanced Solid Tumors
This is a multi-part, open-label, non-randomized phase Ib/II clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of atamparib, an investigational agent, in patients…
- Trial name
- PARP7 (NCT07374419)
- Testing
- atamparib escalation levels, atamparib RP2D
- Where
- China
- Volunteers
- 178 people
- Sponsor
- Nerviano Medical Sciences (Shanghai) Ltd.
Supratentorial Tumors
The Therapeutic Time Window of Mannitol During Craniotomy for Optimal Brain Relaxation in Patients With Supratentorial Tumours
Although mannitol is used for brain relaxation during neurosurgery and in the treatment of raised intracranial pressure; there is not a consensus on its safe, effective dose and the duration of its administration.
- Trial name
- NCT03444519
- Testing
- Mannitol
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Huashan Hospital
Pancreatic Cancer, Neoadjuvant Therapy
Long-term Survival Outcomes According to the Pathologic Response After Neoadjuvant Treatment in PDAC and the Fate of the Patients with Good CAP Grade
1. Neoadjuvant treatment (NAT) is increasingly used in managing pancreatic ductal adenocarcinoma (PDAC), necessitating dependable methods to evaluate tumor response. 2.
- Conditions
- Pancreatic Cancer, Neoadjuvant Therapy, Pathological Complete Response
- Trial name
- CAP with NAT (NCT06630481)
- Testing
- neoadjuvant therapy
- Volunteers
- 462 people
- Sponsor
- Seoul National University Hospital
CRC (Colorectal Cancer)
Efficacy and Safety of Retlirafusp Alfa Plus Bevacizumab and Chemotherapy With or Without Short-Course Radiotherapy in Patients With CRCLM
Efficacy and safety of retlirafusp alfa combined with bevacizumab and chemotherapy with or without short-course radiotherapy in conversion therapy for advanced colorectal cancer liver metastases: an exploratory study.
- Trial name
- NCT07728019
- Testing
- SCRT, Retlirafusp alfa Injection, Bevacizumab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Advanced Solid Tumor
Study of DNP002 in Patients With Solid Tumors
This is an open-label, Phase 1, first-in-human, dose-escalation study designed to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of the anti-Carcinoembryonic-antigen-related-cell-adhesion-molecule-6…
- Trial name
- NCT06466265
- Testing
- DNP002
- Where
- South Korea
- Volunteers
- 36 people
- Sponsor
- Kumho HT Inc.
Leukemia
A Study to Evaluate Available Treatment Information of Ponatinib, Bosutinib, Imatinib, Dasatinib and Nilotinib in Adults With Chronic Myeloid Leukemia
The aims of this study are to learn out about treatment information (including amongst others treatment patterns, safety, development of a participant's condition) ponatinib, bosutinib, imatinib, dasatinib and nilotinib using…
- Trial name
- NCT05743465
- Testing
- No Intervention
- Where
- United States
- Volunteers
- 1,769 people
- Sponsor
- Takeda
Pigmented Villonodular Synovitis, Diffuse-type Giant Cell Tumor
Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor
Nilotinib is a drug that is used to treat a form of a blood cancer called leukemia. Nilotinib works by blocking the action of a protein that might be important for the growth of pigmented villonodular synovitis (PVNS).
- Conditions
- Pigmented Villonodular Synovitis, Diffuse-type Giant Cell Tumor, Tenosynovial Giant Cell Tumor
- Trial name
- NCT01207492
- Testing
- nilotinib
- Where
- 7 sites in United States
- Volunteers
- 17 people
- Sponsor
- Andrew J. Wagner, MD, PhD
Pancreatic Cancer
Gemcitabine and Z650 in Treating Patients With Metastatic or Recurrent Pancreatic Cancer
This phase IB trial is studying how well giving gemcitabine together with Z650 works in treating patients with metastatic or recurrent pancreatic cancer.
- Trial name
- NCT04131192
- Testing
- Z650, Gemcitabine
- Where
- 2 sites in China
- Volunteers
- 13 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Non Small Cell Lung Cancer
Dosage Schedule Study of Pemetrexed Monochemotherapy for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Patients affected by non-small cell lung cancer (NSCLC) will be treated in pemetrexed monochemotherapy regimen for a maximum of 8 cycles.
- Trial name
- NCT00370292
- Testing
- Pemetrexed - Before Protocol Amendment, Pemetrexed - After Protocol Amendment
- Where
- Italy
- Volunteers
- 19 people
- Sponsor
- Eli Lilly and Company
Metastatic Breast Cancer, Locally Advanced Breast Cancer
Study of Artesunate in Metastatic Breast Cancer
The purpose of this study is to evaluation the tolerability of an add-on therapy with artesunate with a duration of 4 weeks in patients with advanced breast cancer.
- Trial name
- ARTIC-M33/2 (NCT00764036)
- Testing
- artesunate
- Where
- Germany
- Volunteers
- 23 people
- Sponsor
- Heidelberg University
Metastatic Renal Cell Carcinoma
Decitabine Combined With Oxaliplatin in Patients With Advanced Renal Cell Carcinoma
The investigators reported previously that epigenetic activation of organic cation transporter (OCT2) by decitabine sensitizes RCC cells to oxaliplatin both in vitro and in xenografts.
- Trial name
- NCT04049344
- Testing
- Decitabine; Oxaliplatin
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Zhejiang Cancer Hospital
Solid Tumors
Study of KRN951 in Patients With Solid Tumors
The purpose of this study is to assess the safety and tolerability of KRN951 administered to patients with solid tumors. In the single dose period, patients in each cohort will receive one oral dose of KRN951 in the first day…
- Trial name
- NCT00970411
- Testing
- KRN951
- Where
- Japan
- Volunteers
- 12 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Lymphoplasmacytic Lymphoma
Vaccine Therapy in Treating Patients With Lymphoplasmacytic Lymphoma
This phase I trial studies the side effects and best dose of vaccine therapy in treating patients with lymphoplasmacytic lymphoma.
- Trial name
- NCT01209871
- Testing
- Autologous Lymphoma Immunoglobulin-derived scFv-chemokine DNA Vaccine, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer Pain
Pilot Trial of an Online Pain Coping Skills Training Program in Spanish
The goal of this pilot study is to assess the feasibility and acceptability of an 8-week online pain coping skills training program designed specifically for Spanish-speaking Hispanic and Latine populations experiencing…
- Trial name
- NCT05917171
- Testing
- painTRAINER
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Wake Forest University Health Sciences
B-cell Lymphoma, Non-Hodgkin's Lymphoma
Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous Transplant
Patients with B-cell lymphoma who relapse after autologous transplant tend to have a poor prognosis. Currently, there is no standard treatment for such patients.
- Trial name
- NCT00434629
- Testing
- Bexxar
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Pennsylvania
Melanoma
Immune Profiles Evolution Under Immunotherapy for Melanoma
The primary objective of the study aims to compare the immune profiles (circulating cytokines and lymphocytes) before and after (6 to 8 weeks) the first infusion of immune checkpoint inhibitors in patients with melanoma treated…
- Trial name
- EPITHEM (NCT04576429)
- Testing
- venous puncture, tumoral biopsy
- Where
- France
- Volunteers
- 360 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Extensive-stage Small-cell Lung Cancer
Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy in Extensive-Stage Small Cell Lung Cancer
This is an open label, phase 2 clinical study to evaluate the safety, tolerability, efficacy, pharmacokinetic (PK) profile, and immunogenicity of QL1706 plus carboplatin and etoposide as first-line therapy in patients with…
- Trial name
- NCT05309629
- Testing
- QL1706, Carboplatin, Etoposide
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Cutaneous Malignant Melanoma
Efficacy and Safety of Nintedanib Combined With Paclitaxel Chemotherapy for Patients With BRAF wt Metastatic Melanoma
This is a multicenter, randomized, double-blind, placebo-controlled phase I/II trial designed to characterize the safety and estimate the efficacy of nintedanib when combined with paclitaxel chemotherapy compared with paclitaxel…
- Trial name
- NIPAWILMA (NCT02308553)
- Testing
- Nintedanib, Paclitaxel
- Where
- 10 sites in Germany
- Volunteers
- 33 people
- Sponsor
- Prof. Dr. med. Dirk Schadendorf
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.